Suggested remit: To appraise the clinical and cost effectiveness of obicetrapib monotherapy within its marketing authorisation for treating primary hypercholesterolaemia or mixed dyslipidaemia. To appraise the clinical and cost effectiveness of obicetrapib–ezetimibe (fixed dose combination) within its marketing authorisation for treating primary hypercholesterolaemia or mixed dyslipidaemia.
- Status:
- In progress
- Technology type:
- Medicine
- Decision:
- Selected
- Reason for decision:
- Anticipate the topic will be of importance to patients, carers, professionals, commissioners and the health of the public to ensure clinical benefit is realised, inequalities in use addressed, and help them make the best use of NHS resources
- Process:
- STA Standard
- ID number:
- 6519
Provisional Schedule
- Committee meeting: 1:
- 04 August 2026
- Expected publication:
- 14 October 2026
Project Team
- Project lead
- Leena Issa
Email enquiries
If you have any queries please email TACommC@nice.org.uk
- External Assessment Group:
- BMJ Technology Assessment Group (BMJ-TAG), BMJ
Stakeholders
- Companies sponsors
- Menarini (obicetrapib, obicetrapib–ezetimibe)
- Others
- Department of Health and Social Care
- NHS England
- Patient carer groups
- Blood Pressure UK
- Cardiac Risk in the Young
- Cardiovascular Care Partnership
- Circulation Foundation
- Gene People
- Genetic Alliance UK
- HEART UK
- Metabolic Support UK
- Pulmonary Hypertension Association UK
- Pumping Marvellous Foundation
- South Asian Health Foundation
- Specialised Healthcare Alliance
- Stroke Association
- Professional groups
- Association of Genetic Nurses & Counsellors
- British & Irish Hypertension Society
- British and Irish Association of Stroke Physicians
- British Association for Nursing in Cardiovascular Care
- British Association of Endocrine and Thyroid Surgeons
- British Atherosclerosis Society
- British Cardiovascular Society
- British Dietetic Association
- British Geriatrics Society
- British Heart Foundation
- British Inherited Metabolic Disease Group
- British Nuclear Cardiology Society
- British Society for Gene and Cell Therapy
- British Society for Genetic Medicine
- British Society for Haematology
- British Society for Haemostasis and Thrombosis
- British Society for Heart Failure
- British Society for Paediatric Endocrinology and Diabetes
- British Society of Cardiovascular Imaging
- British Thoracic Society
- Clinical Leaders of Thrombosis
- National Heart and Lung Institute
- National Metabolic Biochemistry Network
- Neonatal and Paediatric Pharmacy Group
- Primary Care Cardiovascular Society
- Royal College of Emergency Medicine
- Royal College of General Practitioners
- Royal College of Nursing
- Royal College of Paediatrics and Child Health
- Royal College of Pathologists
- Royal College of Physicians
- Royal Pharmaceutical Society
- Royal Society of Medicine
- Society for Cardiological Science & Technology
- Society for Endocrinology
- Society for Vascular Technology of Great Britain and Ireland
- Society of Vascular Nurses
- UK Clinical Pharmacy Association
- Vascular Society of Great Britain & Ireland
- Associated public health groups
- Public Health Wales
- UK Health Security Agency
- Comparator companies
- Amarox (atorvastatin, rosuvastatin)
- Amgen (evolocumab)
- Aspire Pharma (fluvastatin)
- AstraZeneca (rosuvastatin)
- Aurobindo Pharma - Milpharm (atorvastatin, ezetimibe, pravastatin, rosuvastatin, simvastatin)
- Biocon Pharma (rosuvastatin)
- Brown & Burk (atorvastatin, rosuvastatin, simvastatin)
- Daiichi Sankyo (bempedoic acid)
- Dr. Reddy's Laboratories (atorvastatin)
- Flamingo Pharma (atorvastatin)
- Glenmark Pharmaceuticals Europe (ezetimibe, rosuvastatin)
- Krka (atorvastatin, ezetimibe, rosuvastatin)
- MSN Laboratories Europe (atorvastatin, rosuvastatin)
- Mylan (atorvastatin)
- Novartis pharmaceuticals (inclisiran)
- Novumgen (rosuvastatin)
- Organon Pharma (ezetimibe, simvastatin)
- Rivopharm (ezetimibe)
- Rosemont Pharmaceuticals (atorvastatin, simvastatin)
- Sandoz (atorvastatin, ezetimibe, fluvastatin, rosuvastatin, simvastatin)
- Sanofi (alirocumab)
- Sun Pharmaceuticals (atorvastatin, rosuvastatin, simvastatin)
- Thame Laboratories (rosuvastatin)
- Zentiva (atorvastatin, ezetimibe, rosuvastatin)
- General commentators
- All Wales Therapeutics and Toxicology Centre
- Allied Health Professionals Federation
- Board of Community Health Councils in Wales
- British National Formulary
- Care Quality Commission
- Department of Health - Northern Ireland
- Healthcare Improvement Scotland
- Medicines and Healthcare products Regulatory Agency
- National Association of Primary Care
- National Pharmacy Association
- NHS Confederation
- NHS Wales Joint Commissioning Committee
- Scottish Medicines Consortium
- Welsh Government
- Relevant research groups
- British Society for Cardiovascular Research
- Cardiac and Cardiology Research Department, Barts
- Cochrane Heart, Stroke and Circulation Thematic Group
- Cochrane Metabolic & Endocrine Disorders Group
- European Council for Cardiovascular Research
- Genomics England
- Heart Research UK
- MRC Clinical Trials Unit
- National Centre for Cardiovascular Preventions and Outcomes
- National Institute for Health & Care Research
- Wellcome Trust
Related links
Timeline
Key events during the development of the guidance:
| Date | Update |
|---|---|
| 05 January 2026 | Invitation to participate |
| 04 November 2025 - 02 December 2025 | Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators: 6519 |
| 04 November 2025 | In progress. Scoping commencing |
| 16 April 2025 | Referral |
| 14 November 2024 | Awaiting development. Status change linked to Topic Selection Decision being set to Selected |
For further information on our processes and methods, please see our CHTE processes and methods manual